We identified cancer-specific responses to paclitaxel and docetaxel in our analysis; most tumours showed worse clinical outcomes at high levels of BUB1 and concomitant expression of taxane response signatures in BUB1 low cohorts, indicating resistance; however, in vitro drug screens negatively correlated with efficacy. This evidence concerns the gene BUB1 and neoplasm.